Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 467

1.

Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA.

Solomon WC, Myint W, Hou S, Kanai T, Tripathi R, Kurt Yilmaz N, Schiffer CA, Matsuo H.

Nucleic Acids Res. 2019 Aug 22;47(14):7676-7689. doi: 10.1093/nar/gkz550.

PMID:
31424549
2.

HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands to Optimize Hydrogen Bonding in the Substrate Envelope.

Rusere LN, Lockbaum GJ, Lee SK, Henes M, Kosovrasti K, Spielvogel E, Nalivaika EA, Swanstrom R, Kurt Yilmaz N, Schiffer CA, Ali A.

J Med Chem. 2019 Aug 6. doi: 10.1021/acs.jmedchem.9b00838. [Epub ahead of print]

PMID:
31386368
3.

Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.

Henes M, Kosovrasti K, Lockbaum GJ, Leidner F, Nachum GS, Nalivaika EA, Bolon DNA, Kurt Yilmaz N, Schiffer CA, Whitfield TW.

Biochemistry. 2019 Aug 19. doi: 10.1021/acs.biochem.9b00446. [Epub ahead of print]

PMID:
31386353
4.

Target-Specific Prediction of Ligand Affinity with Structure-Based Interaction Fingerprints.

Leidner F, Kurt Yilmaz N, Schiffer CA.

J Chem Inf Model. 2019 Aug 19. doi: 10.1021/acs.jcim.9b00457. [Epub ahead of print]

PMID:
31381335
5.

Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia - You can do this at home if you read the instructions.

Schiffer CA.

Haematologica. 2019 Aug;104(8):1508-1511. doi: 10.3324/haematol.2019.222216. No abstract available.

6.

Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance.

Henes M, Lockbaum GJ, Kosovrasti K, Leidner F, Nachum GS, Nalivaika EA, Lee SK, Spielvogel E, Zhou S, Swanstrom R, Bolon DNA, Kurt Yilmaz N, Schiffer CA.

ACS Chem Biol. 2019 Aug 13. doi: 10.1021/acschembio.9b00370. [Epub ahead of print]

PMID:
31361460
7.

NMR and MD studies combined to elucidate inhibitor and water interactions of HIV-1 protease and their modulations with resistance mutations.

Ishima R, Kurt Yilmaz N, Schiffer CA.

J Biomol NMR. 2019 Jul;73(6-7):365-374. doi: 10.1007/s10858-019-00260-6. Epub 2019 Jun 26.

PMID:
31243634
8.

APOBEC3s: DNA-editing human cytidine deaminases.

Silvas TV, Schiffer CA.

Protein Sci. 2019 Sep;28(9):1552-1566. doi: 10.1002/pro.3670. Epub 2019 Jul 10. Review.

PMID:
31241202
9.

Correction to Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.

Lockbaum GJ, Leidner F, Rusere LN, Henes M, Kosovrasti K, Nachum GS, Nalivaika EA, Bolon DNA, Ali A, Kurt Yilmaz N, Schiffer CA.

ACS Infect Dis. 2019 Jun 14;5(6):1044. doi: 10.1021/acsinfecdis.9b00098. Epub 2019 Apr 16. No abstract available.

PMID:
30990653
10.

Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.

Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E.

Oncologist. 2019 Apr 3. pii: theoncologist.2018-0831. doi: 10.1634/theoncologist.2018-0831. [Epub ahead of print]

PMID:
30944185
11.

Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors.

Özen A, Prachanronarong K, Matthew AN, Soumana DI, Schiffer CA.

Crit Rev Biochem Mol Biol. 2019 Feb;54(1):11-26. doi: 10.1080/10409238.2019.1568962. Epub 2019 Mar 1.

PMID:
30821513
12.

The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.

Diab M, Schiffer CA.

Leuk Res. 2019 Apr;79:1-2. doi: 10.1016/j.leukres.2019.02.001. Epub 2019 Feb 11. No abstract available.

PMID:
30776648
13.

Constrained Mutational Sampling of Amino Acids in HIV-1 Protease Evolution.

Boucher JI, Whitfield TW, Dauphin A, Nachum G, Hollins C, Zeldovich KB, Swanstrom R, Schiffer CA, Luban J, Bolon DNA.

Mol Biol Evol. 2019 Apr 1;36(4):798-810. doi: 10.1093/molbev/msz022.

PMID:
30721995
14.

Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.

Lockbaum GJ, Leidner F, Rusere LN, Henes M, Kosovrasti K, Nachum GS, Nalivaika EA, Ali A, Yilmaz NK, Schiffer CA.

ACS Infect Dis. 2019 Feb 8;5(2):316-325. doi: 10.1021/acsinfecdis.8b00336. Epub 2018 Dec 31. Erratum in: ACS Infect Dis. 2019 Jun 14;5(6):1044.

PMID:
30543749
15.

Structural Analysis of the Active Site and DNA Binding of Human Cytidine Deaminase APOBEC3B.

Hou S, Silvas TV, Leidner F, Nalivaika EA, Matsuo H, Kurt Yilmaz N, Schiffer CA.

J Chem Theory Comput. 2019 Jan 8;15(1):637-647. doi: 10.1021/acs.jctc.8b00545. Epub 2018 Dec 11.

16.

HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites.

Potempa M, Lee SK, Kurt Yilmaz N, Nalivaika EA, Rogers A, Spielvogel E, Carter CW Jr, Schiffer CA, Swanstrom R.

J Mol Biol. 2018 Dec 7;430(24):5182-5195. doi: 10.1016/j.jmb.2018.10.022. Epub 2018 Nov 7.

PMID:
30414407
17.

Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.

Prachanronarong KL, Canale AS, Liu P, Somasundaran M, Hou S, Poh YP, Han T, Zhu Q, Renzette N, Zeldovich KB, Kowalik TF, Kurt-Yilmaz N, Jensen JD, Bolon DNA, Marasco WA, Finberg RW, Schiffer CA, Wang JP.

J Virol. 2019 Jan 4;93(2). pii: e01639-18. doi: 10.1128/JVI.01639-18. Print 2019 Jan 15.

18.
19.

A call to arms: Unifying the fight against resistance.

Kaushansky A, Hedstrom L, Goldman A, Singh J, Yang PL, Rathod PK, Cynamon M, Wodarz D, Mahadevan D, Tomaras A, Navia MA, Schiffer CA.

Sci Signal. 2018 Oct 23;11(553). pii: eaav0442. doi: 10.1126/scisignal.aav0442.

PMID:
30352947
20.

Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis.

Seymour EK, Ruterbusch JJ, Beebe-Dimmer JL, Schiffer CA.

Cancer. 2019 Jan 1;125(1):135-143. doi: 10.1002/cncr.31738. Epub 2018 Oct 21.

PMID:
30343488
21.

Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.

Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA.

Structure. 2018 Oct 2;26(10):1360-1372.e5. doi: 10.1016/j.str.2018.07.004. Epub 2018 Aug 23.

PMID:
30146168
22.

Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants.

Rusere LN, Matthew AN, Lockbaum GJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A.

ACS Med Chem Lett. 2018 May 17;9(7):691-696. doi: 10.1021/acsmedchemlett.8b00150. eCollection 2018 Jul 12.

23.

Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA.

Maiti A, Myint W, Kanai T, Delviks-Frankenberry K, Sierra Rodriguez C, Pathak VK, Schiffer CA, Matsuo H.

Nat Commun. 2018 Jun 25;9(1):2460. doi: 10.1038/s41467-018-04872-8.

24.

Substrate sequence selectivity of APOBEC3A implicates intra-DNA interactions.

Silvas TV, Hou S, Myint W, Nalivaika E, Somasundaran M, Kelch BA, Matsuo H, Kurt Yilmaz N, Schiffer CA.

Sci Rep. 2018 May 14;8(1):7511. doi: 10.1038/s41598-018-25881-z.

25.

The evolution of dasatinib dosage over the years and its relevance to other anticancer medications.

Schiffer CA.

Cancer. 2018 Jul 1;124(13):2687-2689. doi: 10.1002/cncr.31516. Epub 2018 May 3. No abstract available.

26.

Assembly of human C-terminal binding protein (CtBP) into tetramers.

Bellesis AG, Jecrois AM, Hayes JA, Schiffer CA, Royer WE Jr.

J Biol Chem. 2018 Jun 8;293(23):9101-9112. doi: 10.1074/jbc.RA118.002514. Epub 2018 Apr 26.

27.

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.

Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE.

BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1.

28.

Hydration Structure and Dynamics of Inhibitor-Bound HIV-1 Protease.

Leidner F, Kurt Yilmaz N, Paulsen J, Muller YA, Schiffer CA.

J Chem Theory Comput. 2018 May 8;14(5):2784-2796. doi: 10.1021/acs.jctc.8b00097. Epub 2018 Apr 18.

29.

Synonymous Mutations at the Beginning of the Influenza A Virus Hemagglutinin Gene Impact Experimental Fitness.

Canale AS, Venev SV, Whitfield TW, Caffrey DR, Marasco WA, Schiffer CA, Kowalik TF, Jensen JD, Finberg RW, Zeldovich KB, Wang JP, Bolon DNA.

J Mol Biol. 2018 Apr 13;430(8):1098-1115. doi: 10.1016/j.jmb.2018.02.009. Epub 2018 Feb 18.

PMID:
29466705
30.

Probing Structural Changes among Analogous Inhibitor-Bound Forms of HIV-1 Protease and a Drug-Resistant Mutant in Solution by Nuclear Magnetic Resonance.

Khan SN, Persons JD, Paulsen JL, Guerrero M, Schiffer CA, Kurt-Yilmaz N, Ishima R.

Biochemistry. 2018 Mar 13;57(10):1652-1662. doi: 10.1021/acs.biochem.7b01238. Epub 2018 Feb 19.

31.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS.

Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925. eCollection 2017 Jun 27.

32.

Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope.

Avnir Y, Prachanronarong KL, Zhang Z, Hou S, Peterson EC, Sui J, Zayed H, Kurella VB, McGuire AT, Stamatatos L, Hilbert BJ, Bohn MF, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Goodall M, Jefferis R, Zhu Q, Kurt Yilmaz N, Schiffer CA, Marasco WA.

Cell Rep. 2017 Dec 12;21(11):3243-3255. doi: 10.1016/j.celrep.2017.11.056.

33.

"Epigenetic" modification as therapy for acute myeloid leukemia.

Schiffer CA.

Cancer. 2018 Jan 15;124(2):242-244. doi: 10.1002/cncr.31137. Epub 2017 Dec 6. No abstract available.

34.

Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C InfectionPublished as part of the Biochemistry series "Biochemistry to Bedside".

Matthew AN, Kurt Yilmaz N, Schiffer CA.

Biochemistry. 2018 Feb 6;57(5):481-482. doi: 10.1021/acs.biochem.7b01160. Epub 2017 Dec 1. No abstract available.

PMID:
29192768
35.

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, Omel JL, Rainey JM, Rebulla P, Rowley SD, Troner MB, Anderson KC.

J Clin Oncol. 2018 Jan 20;36(3):283-299. doi: 10.1200/JCO.2017.76.1734. Epub 2017 Nov 28.

PMID:
29182495
36.

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Schiffer CA, Bohlke K, Anderson KC.

J Oncol Pract. 2018 Feb;14(2):129-133. doi: 10.1200/JOP.2017.028902. Epub 2017 Nov 28. No abstract available.

PMID:
29182492
37.

Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic Leukemia.

Seymour EK, Schiffer CA, de Souza JA.

J Oncol Pract. 2017 Dec;13(12):e1002-e1011. doi: 10.1200/JOP.2017.024778. Epub 2017 Nov 16.

PMID:
29144866
38.

CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.

Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11751-11756. doi: 10.1073/pnas.1708268114. Epub 2017 Oct 16.

39.

Elucidating the Interdependence of Drug Resistance from Combinations of Mutations.

Ragland DA, Whitfield TW, Lee SK, Swanstrom R, Zeldovich KB, Kurt-Yilmaz N, Schiffer CA.

J Chem Theory Comput. 2017 Nov 14;13(11):5671-5682. doi: 10.1021/acs.jctc.7b00601. Epub 2017 Oct 9.

40.

Citrullination of NF-κB p65 promotes its nuclear localization and TLR-induced expression of IL-1β and TNFα.

Sun B, Dwivedi N, Bechtel TJ, Paulsen JL, Muth A, Bawadekar M, Li G, Thompson PR, Shelef MA, Schiffer CA, Weerapana E, Ho IC.

Sci Immunol. 2017 Jun 9;2(12). pii: eaal3062. doi: 10.1126/sciimmunol.aal3062.

41.

Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.

Matthew AN, Zephyr J, Hill CJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt-Yilmaz N, Schiffer CA, Ali A.

J Med Chem. 2017 Jul 13;60(13):5699-5716. doi: 10.1021/acs.jmedchem.7b00426. Epub 2017 Jun 19.

42.

Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity.

Kouno T, Silvas TV, Hilbert BJ, Shandilya SMD, Bohn MF, Kelch BA, Royer WE, Somasundaran M, Kurt Yilmaz N, Matsuo H, Schiffer CA.

Nat Commun. 2017 Apr 28;8:15024. doi: 10.1038/ncomms15024.

43.

Transplantation for Myeloma - Now or Later?

Schiffer CA, Zonder JA.

N Engl J Med. 2017 Apr 6;376(14):1378-1379. doi: 10.1056/NEJMe1700453. No abstract available.

PMID:
28379801
44.

Interdependence of Inhibitor Recognition in HIV-1 Protease.

Paulsen JL, Leidner F, Ragland DA, Kurt Yilmaz N, Schiffer CA.

J Chem Theory Comput. 2017 May 9;13(5):2300-2309. doi: 10.1021/acs.jctc.6b01262. Epub 2017 Apr 11.

45.

Point: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.

Schiffer CA.

Oncology (Williston Park). 2017 Mar 15;31(3):190-1. No abstract available.

46.

Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.

Lin KH, Ali A, Rusere L, Soumana DI, Kurt Yilmaz N, Schiffer CA.

J Virol. 2017 Apr 28;91(10). pii: e00045-17. doi: 10.1128/JVI.00045-17. Print 2017 May 15.

47.

Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.

Prachanronarong KL, Özen A, Thayer KM, Yilmaz LS, Zeldovich KB, Bolon DN, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Kurt-Yilmaz N, Schiffer CA.

J Chem Theory Comput. 2016 Dec 13;12(12):6098-6108. Epub 2016 Nov 17.

PMID:
27951676
48.

Structural and molecular analysis of a protective epitope of Lyme disease antigen OspA and antibody interactions.

Shandilya S, Kurt Yilmaz N, Sadowski A, Monir E, Schiller ZA, Thomas WD Jr, Klempner MS, Schiffer CA, Wang Y.

J Mol Recognit. 2017 May;30(5). doi: 10.1002/jmr.2595. Epub 2016 Nov 16.

49.

Dengue Protease Substrate Recognition: Binding of the Prime Side.

Lin KH, Nalivaika EA, Prachanronarong KL, Yilmaz NK, Schiffer CA.

ACS Infect Dis. 2016 Oct 14;2(10):734-743. Epub 2016 Sep 22.

50.

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.

Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA.

J Am Chem Soc. 2016 Sep 14;138(36):11850-9. doi: 10.1021/jacs.6b06454. Epub 2016 Sep 2.

Supplemental Content

Loading ...
Support Center